A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)

Trial Profile

A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Nivolumab (Primary) ; BMS 986016; Dasatinib; Ipilimumab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms FRACTION-Lung
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 30 Nov 2016 Number of treatment arms changed from 3 to 4. Drug ipilimumab was to added to the regimen.
    • 11 Oct 2016 Trial design was presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top